CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.25B, above the global median of $1.18B
- FinancialsAltman Z-Score 0.71: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.25BUSDvs all stocks (USD)
Revenue (TTM)
1.65BUSDvs all stocks (USD)
Profit Margin
-0.44%vs Medical Devices peers
Beta
1.21xvs all stocks
52-Week Change
18.27%vs all stocks
Market Capitalization
1.25BUSDvs all stocks (USD)
Enterprise Value
3.03BUSDvs all stocks (USD)
Forward P/E
6.18xvs Medical Devices peers
Price to Sales (TTM)
0.7609xvs Medical Devices peers
Price to Book (MRQ)
1.20xvs Medical Devices peers
Enterprise to Revenue
1.84xvs Medical Devices peers
Enterprise to EBITDA
9.56xvs Medical Devices peers
Gross Margin
52.47%vs Medical Devices peers
Profit Margin
-0.44%vs Medical Devices peers
Operating Margin
9.62%vs Medical Devices peers
Return on Assets (TTM)
2.83%vs Medical Devices peers
Return on Equity (TTM)
-0.70%vs Medical Devices peers
Revenue (TTM)
1.65BUSDvs all stocks (USD)
Revenue per Share (TTM)
21.41USDUpdated Sep 27, 2026Quarterly Revenue Growth
0.80%vs Medical Devices peers
Gross Profit (TTM)
937.07MUSDvs all stocks (USD)
EBITDA (TTM)
245.19MUSDvs all stocks (USD)
Net Income (TTM)
-7.24MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
0.76%vs Medical Devices peers
Operating Cash Flow (TTM)
85.33MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
94.40MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
1.64BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
803.63MUSDFY2025 · Dec 31, 2025Gross Profit
831.62MUSDFY2025 · Dec 31, 2025Operating Income
18.00MUSDvs all stocks (USD)
Pre-tax Income
-563.50MUSDFY2025 · Dec 31, 2025Income Tax Expense
-47.03MUSDFY2025 · Dec 31, 2025Net Income
-516.47MUSDFY2025 · Dec 31, 2025EBIT
-477.25MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
185.95MUSDFY2025 · Dec 31, 2025Research & Development
98.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
699.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
18.47MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
86.25MUSDFY2025 · Dec 31, 2025EPS (Basic)
-6.74USDFY2025 · Dec 31, 2025EPS (Diluted)
-6.74USDFY2025 · Dec 31, 2025Basic Shares Outstanding
76.67MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
76.67MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-516.47MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-458.67MUSDFY2025 · Dec 31, 2025Free Cash Flow
-540.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
235.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-516.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
151.83MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-66.26MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.58MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-15.41MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-485.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
26.72MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-57.17MUSDFY2025 · Dec 31, 2025Capital Expenditures
-81.44MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-14.20MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-19.43MUSDFY2025 · Dec 31, 2025Sale of Investments
7.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-93.86MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
720.70MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-669.89MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-221.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-23.21MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
27.38MUSDFY2025 · Dec 31, 2025Shares Outstanding
77.78MSharesUpdated Sep 27, 2026Float Shares
58.68MSharesUpdated Sep 27, 2026Shares Short
6.81MSharesUpdated Sep 27, 2026Short Ratio
9.84daysvs all stocks
Short % of Shares Outstanding
12.07%vs all stocks
% Held by Insiders
14.30%vs all stocks
% Held by Institutions
98.67%vs all stocks
Total Cash (MRQ)
274.08MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.52USDUpdated Sep 27, 2026Total Debt (MRQ)
2.05BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.96xvs Medical Devices peers
Current Ratio (MRQ)
3.60xvs Medical Devices peers
Book Value per Share (MRQ)
13.41USDUpdated Sep 27, 2026Total Assets
3.60BUSDvs all stocks (USD)
Total Current Assets
1.16BUSDFY2025 · Dec 31, 2025Total Liabilities
2.56BUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.44BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.10BUSDFY2025 · Dec 31, 2025Total Current Liabilities
455.98MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
235.05MUSDFY2025 · Dec 31, 2025Other Short-term Investments
28.69MUSDFY2025 · Dec 31, 2025Accounts Receivable
278.85MUSDFY2025 · Dec 31, 2025Inventory
492.74MUSDFY2025 · Dec 31, 2025Accounts Payable
95.73MUSDFY2025 · Dec 31, 2025Short-term Debt
140.57MUSDFY2025 · Dec 31, 2025Deferred Revenue
11.46MUSDFY2025 · Dec 31, 2025Long-term Debt
1.89BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
204.28MUSDFY2025 · Dec 31, 2025Common Stock (Book)
923.00KUSDFY2025 · Dec 31, 2025Retained Earnings
423.44MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.04BUSDvs all stocks (USD)
Treasury Stock
689.21MUSDFY2025 · Dec 31, 202552-Week Low
8.70USDUpdated Sep 27, 202652-Week High
20.49USDUpdated Sep 27, 202652-Week Change
18.27%vs all stocks
Beta
1.21xvs all stocks
50-Day MA
17.08USDUpdated Sep 27, 2026200-Day MA
14.00USDUpdated Sep 27, 2026Avg 10-Day Volume
1.08MSharesUpdated Sep 27, 2026Avg 30-Day Volume
784.00KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.0900USDUpdated Sep 27, 2026Other Income / Expense
-513.72MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.52Profit Margin: -0.00
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.60Altman Z-Score: 0.71
Financial Health
Altman Z-Score 0.71: distress zoneCritical
Altman Z-Score: 0.71
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.25B, above the global median of $1.18BNotable
Market cap (USD): 1,253,692,796Global Median: 1,180,223,658.953
Revenue is $1.65B, above the global median of $548.88MNotable
Revenue (USD): 1,647,666,048Global Median: 548,883,780.48
Levered free cash flow is $94.4M, above the global median of $18.73MNotable
Levered free cash flow (USD): 94,402,000Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Changzhou Qianhong Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai MicroPort EP MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harrow Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bicara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Immatics N.V.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jiangsu Yahong Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Asia Cuanon Technology Co. Ltd.
1 interpretationWithin or Near the Altman Distress Zone
Kosmos Energy Ltd.
1 interpretationWithin or Near the Altman Distress Zone
Datang Telecom Technology Co. Ltd.
1 interpretationWithin or Near the Altman Distress Zone